<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Evaluation-Frameworks on Athan Dial - Portfolio</title>
    <link>https://athan-dial.github.io/tags/evaluation-frameworks/</link>
    <description>Recent content in Evaluation-Frameworks on Athan Dial - Portfolio</description>
    <generator>Hugo</generator>
    <language>en</language>
    <lastBuildDate>Fri, 09 Jan 2026 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://athan-dial.github.io/tags/evaluation-frameworks/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Preventing Metric Theater in Drug Discovery ML</title>
      <link>https://athan-dial.github.io/case-studies/preventing-metric-theater-drug-discovery-ml/</link>
      <pubDate>Fri, 09 Jan 2026 00:00:00 +0000</pubDate>
      <guid>https://athan-dial.github.io/case-studies/preventing-metric-theater-drug-discovery-ml/</guid>
      <description>&lt;h2 id=&#34;context&#34;&gt;Context&lt;/h2&gt;&#xA;&lt;p&gt;Data science teams were presenting accuracy metrics without reliability monitoring, creating false confidence in model predictions for multimillion-dollar compound selection decisions. The stakes were high: each compound decision represented $2M+ in development costs, but teams lacked visibility into model performance degradation over time.&lt;/p&gt;&#xA;&lt;p&gt;This work lived in the drug discovery ML platform, where prediction models guide which compounds advance to expensive in-vitro and in-vivo testing phases. My role was to own the evaluation framework design and establish decision forums with clear ownership.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
